Investors

Overview

Corporate Profile

Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Latest News

View All
Mar 21, 2019

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

Read More
Feb 25, 2019

Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Read More
Feb 23, 2019

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Read More
Feb 21, 2019

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

Read More
Feb 19, 2019

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Read More
Feb 14, 2019

Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting

Read More
Jan 24, 2019

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

Read More
Jan 22, 2019

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

Read More
Jan 07, 2019

Gamida Cell Announces 2019 Goals and Provides Company Update

Read More
Dec 04, 2018

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Read More
Dec 03, 2018

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Read More
Nov 28, 2018

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Read More
Nov 01, 2018

Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting

Read More
Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Read More
Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Read More
Aug 06, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Read More
Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Read More
Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Read More
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More
Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Read More
Upcoming Events
More events are coming soon.
Recent Events

Investor & Media Contact

Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com